Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
TNXP=MC $11 M another LIFETIME OPP trading under cash and with major milestones around the corner see chart below ..Could hit $5++ easily ahead of the phase 3 interim results expected this Quarter and if positive this low float gem could run toward $20 .GL
Tonix Pharma (TNXP)
Market Cap: $11 M
Cash: $18 M
Price:$1.30 M
Shares Out: 8.5 M
TNXP=MC $11 M another LIFETIME OPP trading under cash and with major milestones around the corner see chart below ..Could hit $5++ easily ahead of the phase 3 interim results expected this Quarter and if positive this low float gem could run toward $20 .GL
Tonix Pharma (TNXP)
Market Cap: $11 M
Cash: $18 M
Price:$1.30 M
Shares Out: 8.5 M
KAAABOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOM load up while its terrible undervalued..this goldmine likely to run towards $4+ in the coming weeks
may be they still didnt realize the monster potential here
CHAAACHINGGGGGGGGGGGGGGGGGGGGGGG load up while its still terrible underpriced
RALLLLYYYYYYYYYYYYYYYYYYYYYYYYYYyy continues
CYTR = MC$16 M -GREAT NEWS OUT by drug partner Orphazyme..still trading UNDER Cash balance
Orphazyme announces US Early Access Program for Niemann-Pick disease Type C
https://www.globenewswire.com/news-release/2020/01/06/1966421/0/en/Orphazyme-announces-US-Early-Access-Program-for-Niemann-Pick-disease-Type-C.html
The EAP provides a pathway for patients with serious, life-threatening diseases or conditions who lack therapeutic alternatives to gain access to investigational drugs before they are approved.
Kim Stratton, Chief Executive Officer, commented, “Orphazyme is deeply committed to providing access to new therapies for people living with rare diseases such as NPC. There are currently no approved products to treat NPC in the US and we are pleased to make arimoclomol, a potential first-in-class innovative oral therapy, available pre-commercially to US patients through this program. We plan to file for approval of arimoclomol in the US in H1 2020”.
CYTR thread for more infos about the stock
https://investorshub.advfn.com/CytRx-Corp-CYTR-3392/
CYTR = MC$16 M -GREAT NEWS OUT by drug partner Orphazyme..still trading UNDER Cash balance
Orphazyme announces US Early Access Program for Niemann-Pick disease Type C
https://www.globenewswire.com/news-release/2020/01/06/1966421/0/en/Orphazyme-announces-US-Early-Access-Program-for-Niemann-Pick-disease-Type-C.html
The EAP provides a pathway for patients with serious, life-threatening diseases or conditions who lack therapeutic alternatives to gain access to investigational drugs before they are approved.
Kim Stratton, Chief Executive Officer, commented, “Orphazyme is deeply committed to providing access to new therapies for people living with rare diseases such as NPC. There are currently no approved products to treat NPC in the US and we are pleased to make arimoclomol, a potential first-in-class innovative oral therapy, available pre-commercially to US patients through this program. We plan to file for approval of arimoclomol in the US in H1 2020”.
CYTR thread for more infos about the stock
https://investorshub.advfn.com/CytRx-Corp-CYTR-3392/
Good News out today from partner Orphazyme
Orphazyme announces US Early Access Program for Niemann-Pick disease Type C ..
https://www.globenewswire.com/news-release/2020/01/06/1966421/0/en/Orphazyme-announces-US-Early-Access-Program-for-Niemann-Pick-disease-Type-C.html
breaks through 200 day moving average which likely will attract more buyers to this brutally underpriced goldmine ...could run towards $2 next week
https://stockcharts.com/h-sc/ui?s=cytr
$4-6 in the coming months is possible even at $6 the market cap would be just around $200 million which is still low . this one is a BIG BIG Opp
load up guys while its still a PURE GIFT HERE
CYTR = UP 18% RALLYYYYYY ..Market Cap still at laughable $14 million
CYTR = MCap $12 M / Cash till 2023 / Rare Disease Drug close to Approval / MULTIPLE Phase 3 & P2 ongoing =´A REAL MONSTER OPP guys
https://investordeck.s3.amazonaws.com/images/1Prhelz9W0OB2lbHKE5HQ_15?AWSAccessKeyId=AKIAIYK6VHI5CSQ2BMIA&
BOOOOOOOOOOOOOOOOOOOOOOOOOOOOOM
RALLYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY and still a MEGA GIFT
back in green ..stock is extremely underpriced
take a look at CYTR guys ..could run like IPCIF did extremely undervalued and has large pipeline
https://investorshub.advfn.com/CytRx-Corp-CYTR-3392/
CYTR = MC $11 M..Another MEGA OPP to get in cheap
https://investorshub.advfn.com/CytRx-Corp-CYTR-3392/
CYTR = MC $11 M..Another MEGA OPP to get in cheap
https://investorshub.advfn.com/CytRx-Corp-CYTR-3392/
CHEAPEST Bio gem out there
More Good News out today ...
Orphazyme reports positive arimoclomol data from open-label phase 2/3 extension in Niemann-Pick disease Type C
https://www.globenewswire.com/news-release/2020/01/03/1965891/0/en/Orphazyme-reports-positive-arimoclomol-data-from-open-label-phase-2-3-extension-in-Niemann-Pick-disease-Type-C.html
CYTR.. moving higher and higher .. get some guys before she hits $1++ currently at laughable 37 cents or $12 million valuation
KAAABOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOM
RALLYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY i love it and still a MEGA GIFT here
CYTR now up 24% ...market cap still at unbelievable $12 million again this one could be the HIGHFLYER 2020...enjoy the ride guys
CYTR =MC $10 M /Trading below Cash/ First US & European approval for Rare Disease Drug likely later this year / MULTIPLE Phase 3 & P2 programs ongoing = A LIETIME OPP ..my tgt is $5
$1++ coming ..get some before she runs higher
CYTR =MC $10 M--A LIFETIME OPP GUYS ,,take a look at their 2 pipeline charts and upcoming catalysts below ..First Approval in USA and Europe likely later this year for a Drug targeting Rare Disease (Niemann-Pick Diesease) for which there is NO approved treatment in USA .
CTYR = BRUTALLY underpriced at a market cap of $10 million which is below their Cash balance of $18.5 million (Cash till 2023+) . They have lots of Phase 3 and Phase 2 programs ongoing targeting Rare Diseases and Cancer .
This Low float stock could be a 10+ bagger easily guys and even then it would be cheap at around $100 million valuation .STRONG BUY
CytRx (CYTR)
Market-Cap: $9,8 M
Cash: $18,5 M ( Cash untill 2023+ )
Price: $0,29
Shares Out: 33,6 M
Burn-rate: only $1.2 M per Quarter
NO Debt
Presentation December 2019
http://www.cytrx.com/wp-content/uploads/2019/12/CYTR-Corp-Overview-December-2019-Non-Conf.pdf
CytRx Corporation Highlights Significant Positive Events From its Two Licensed Drugs Arimoclomol and Aldoxorubicin ....December 19, 2019
http://www.cytrx.com/wp-content/uploads/2019/12/CYTR-Highlights-TripleNegBreastResultsDec19_FINAL.pdf
$1+ before end of this month ,, stock is a mega GIFT at $11 million valuation
RALLYYYYYYYYYYYYYYYYYYYYYYY
BID/ASK going up....stock is a MEGA gift at this price
https://www.otcmarkets.com/stock/CYTR/overview